SOFTBANK
21.6.2022 21:11:04 CEST | Business Wire | Press release
SoftBank Group Corp. (“SoftBank”) today announced that Alex Clavel, currently Managing Partner at SoftBank Group International (“SBGI”), has been appointed as Chief Executive Officer of SBGI, effective June 30, 2022. Mr. Clavel will succeed Michel Combes, who has decided to leave SoftBank to pursue new opportunities.
Mr. Clavel will bring seven years of leadership experience at SoftBank across Tokyo, Silicon Valley and New York to the role, in which he will oversee SBGI’s operations and investment portfolio, including its stakes in Boston Dynamics, SoFi, Fortress, T-Mobile, Arm, among other portfolio companies. Together with the SoftBank Vision Funds, SBGI is responsible for all SoftBank Group Corp. activities outside of Japan, including across Europe, the U.S., Asia and Latin America.
Masayoshi Son, Representative Director, Corporate Officer, Chairman & CEO of SoftBank Group Corp., said, “Building on more than two decades of experience in corporate development and investing, Alex has long been a trusted leader at SoftBank in multiple locations around the globe. I am confident that his experience – combined with the strong SoftBank team around him – will serve us well as we continue our journey as Vision Capitalists.”
Mr. Son continued, “I want to thank Michel for his crucial contributions to SoftBank over the past five years. He has played a critical role in some of our most important investments and assets, and I wish him all the best with his future plans. I’m glad he will remain part of the SoftBank family by continuing to represent us on various portfolio company boards.”
Mr. Clavel commented, “I am honored by the trust Masa has placed in me to lead SBGI and am fortunate to have worked alongside Michel. I am excited to build on our success and for what’s to come.”
Mr. Combes said, “It has been a pleasure to work with Masa and the talented teams across SoftBank. I am departing SoftBank proud of having achieved what I set out to do here, including turning around Sprint and executing its merger with T-Mobile, repositioning WeWork and successfully taking it public, and, most recently, the integration of the SoftBank Latin America Funds into the Vision Fund, as well as overseeing SoftBank’s strategic investments in French and European portfolio companies. I am pleased to pass the baton to Alex. He has been my partner for the past two years and I am confident he’s well positioned to lead the team and carry forward our success into the future.”
Alex Clavel Biographical Information
Most recently, Mr. Clavel has been responsible for managing several of SoftBank’s international platform of investments outside of the Vision Funds, including T-Mobile, Deutsche Telecom, WeWork and OneWeb. He serves as a director on the boards of numerous companies and investment vehicles, including Arm China, Boston Dynamics, InMobi, SB Energy, Goggo, and Levere Holdings Corp. Mr. Clavel joined SoftBank in Tokyo in 2015 and worked in SoftBank’s Silicon Valley office before moving to New York with SoftBank in 2018.
Prior to joining SoftBank, Mr. Clavel spent 19 years at Morgan Stanley in investment banking, where he focused on technology, media and telecom M&A. He graduated from Princeton University and speaks French, Japanese and Mandarin Chinese.
About SoftBank Group
The SoftBank Group invests in breakthrough technology to improve the quality of life for people around the world. The SoftBank Group is comprised of SoftBank Group Corp. (TOKYO: 9984), an investment holding company that includes stakes in telecommunications, internet services, AI, smart robotics, IoT and clean energy technology providers; the SoftBank Vision Funds, which are investing more than US$140 billion to help extraordinary entrepreneurs transform industries and shape new ones; the US$8 billion SoftBank Latin America Funds; and investments in underrepresented founders, including the SB Opportunity Fund, a US$100+ million fund investing in Black, Latinx and Native American founders, and SoftBank Investment Advisers’ global Emerge program. To learn more, please visit https://group.softbank/en .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621006036/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom